Gold Investment Management Ltd. Buys 1,428 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Gold Investment Management Ltd. lifted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 2.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 73,204 shares of the company’s stock after purchasing an additional 1,428 shares during the period. Gold Investment Management Ltd.’s holdings in Takeda Pharmaceutical were worth $1,049,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Summit Global Investments grew its holdings in Takeda Pharmaceutical by 86.0% in the 3rd quarter. Summit Global Investments now owns 415,558 shares of the company’s stock worth $5,909,000 after acquiring an additional 192,143 shares during the last quarter. AlphaCentric Advisors LLC purchased a new stake in Takeda Pharmaceutical in the third quarter worth about $1,138,000. Catalyst Capital Advisors LLC increased its position in Takeda Pharmaceutical by 7.2% during the 3rd quarter. Catalyst Capital Advisors LLC now owns 178,000 shares of the company’s stock valued at $2,531,000 after buying an additional 12,000 shares in the last quarter. PDS Planning Inc purchased a new stake in shares of Takeda Pharmaceutical in the third quarter worth $148,000. Finally, QRG Capital Management Inc. raised its position in shares of Takeda Pharmaceutical by 4.5% in the 3rd quarter. QRG Capital Management Inc. now owns 282,154 shares of the company’s stock worth $4,012,000 after purchasing an additional 12,035 shares during the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Down 0.9 %

Shares of NYSE:TAK traded down $0.12 during trading on Friday, reaching $13.74. 84,964 shares of the stock traded hands, compared to its average volume of 1,825,528. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $15.08. The stock has a market cap of $43.72 billion, a P/E ratio of 23.90, a price-to-earnings-growth ratio of 0.26 and a beta of 0.54. The stock has a 50-day moving average of $14.42 and a two-hundred day moving average of $13.81. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.77 and a current ratio of 1.28.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.